Kritische Blicke auf die Coronakrise und ihre Folgen
Kritische Blicke auf die Coronakrise und ihre Folgen

Effects of Omicron

Christina Menni, Ana M. Valdez, Tim D. Spector u. a.: Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study, in: The Lancet Vol. 399, Issue 10335 (April 23, 2022), pp. 1618-1624.



The SARS-CoV-2 variant of concern, omicron, appears to be less severe than delta. The authors aim to quantify the differences in symptom prevalence, risk of hospital admission, and symptom duration among the vaccinated population.


In this prospective longitudinal observational study, the authors collected data from participants who were self-reporting test results and symptoms in the ZOE COVID app (previously known as the COVID Symptoms Study App). Eligible participants were aged 16–99 years, based in the UK, with a body-mass index between 15 and 55 kg/m², had received at least two doses of any SARS-CoV-2 vaccine, were symptomatic, and logged a positive symptomatic PCR or lateral flow result for SARS-CoV-2 during the study period. The primary outcome was the likelihood of developing a given symptom (of the 32 monitored in the app) or hospital admission within 7 days before or after the positive test in participants infected during omicron prevalence compared with those infected during delta prevalence.


Between June 1, 2021, and Jan 17, 2022, the authors identified 63,002 participants who tested positive for SARS-CoV-2 and reported symptoms in the ZOE app. These patients were matched 1:1 for age, sex, and vaccination dose, across two periods (June 1 to November 27, 2021, delta prevalent at >70%; n=4990, and December 20, 2021, to January 17, 2022, omicron prevalent at >70%; n=4990). Loss of smell was less common in participants infected during omicron prevalence than during delta prevalence (16.7% vs 52.7%, odds ratio [OR] 0.17; 95% CI 0.16–0.19, p<0.001). Sore throat was more common during omicron prevalence than during delta prevalence (70.5% vs 60.8%, 1.55; 1.43–1.69, p<0.001). There was a lower rate of hospital admission during omicron prevalence than during delta prevalence (1.9% vs 2.6%, OR 0.75; 95% CI 0.57–0.98, p=0.03).


The prevalence of symptoms that characterise an omicron infection differs from those of the delta SARS-CoV-2 variant, apparently with less involvement of the lower respiratory tract and reduced probability of hospital admission. The authors data indicate a shorter period of illness and potentially of infectiousness which should impact work–health policies and public health advice.


Wellcome Trust, ZOE, National Institute for Health Research, Chronic Disease Research Foundation, National Institutes of Health, and Medical Research Council

Link to the article on the site

Link to download the articlea PDF file from the site